United Therapeutics (UTHR) Finished Goods (2010 - 2020)

United Therapeutics has disclosed Finished Goods across 11 years of filings, most recently posting $43.8 million for Q1 2020.

• Finished Goods for Q1 2020 came in at $43.8 million, down 7.98% year-over-year; the trailing twelve-month figure through Mar 2020 was $43.8 million (down 7.98% YoY), and the FY2019 annual result was $43.2 million, down 11.29% from the prior year.
• Finished Goods came in at $43.8 million for Q1 2020 at United Therapeutics, up from $43.2 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $62.2 million in Q3 2017 to a low of $37.3 million in Q2 2016.
• The 5-year median for Finished Goods is $48.7 million (2018), against an average of $48.9 million.
• Across the five-year window, Finished Goods jumped 65.15% in 2017 and fell 20.58% in 2018, its largest moves.
• United Therapeutics' Finished Goods stood at $49.7 million in 2016, then gained by 12.47% to $55.9 million in 2017, then retreated by 12.88% to $48.7 million in 2018, then dropped by 11.29% to $43.2 million in 2019, then rose by 1.39% to $43.8 million in 2020.
• The last three Finished Goods figures came in at $43.8 million (Q1 2020), $43.2 million (Q4 2019), and $45.0 million (Q3 2019), per Business Quant data.